TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31530665

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 514

Group type: COMPARATOR
Intervention: continued GLP-1 RA therapy
Number of subjects: 514
Study: 29978268

Group type: EXPERIMENTAL
Intervention: 940-nm diode laser treatment after undisplaced flap surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (surgery without laser treatment)
Number of subjects: 30
Study: 26429974

Group type: EXPERIMENTAL
Intervention: Discontinue ACEi, ARB or combination of both (experimental arm)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Continue ACEi, ARB or combination of both (control arm)
Number of subjects: 410
Study: 23957716

Group type: EXPERIMENTAL
Intervention: AC + AET (doxorubicin plus cyclophosphamide with aerobic training)
Number of subjects: 20

Group type: COMPARATOR
Intervention: AC (doxorubicin plus cyclophosphamide)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: AC + AET
Number of subjects: 20

Group type: COMPARATOR
Intervention: AC
Number of subjects: 20
Study: 22318559

Group type: EXPERIMENTAL
Intervention: Fixed pushing speed (FPS) at 80-100% maximal speed
Number of subjects: 20

Group type: COMPARATOR
Intervention: Self-selected pushing speed (SPS)
Number of subjects: 20
Study: 19550210

Group type: EXPERIMENTAL
Intervention: Online colposcopic image assessment
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Online colpophotographic assessment of high-grade disease
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: High-grade diagnosis by Reid Index scoring
Number of subjects: 919

Group type: COMPARATOR
Intervention: Same-day enrollment colposcopy
Number of subjects: 919
Study: 17472819

Group type: EXPERIMENTAL
Intervention: Arformoterol 15 microg BID
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Arformoterol 25 microg BID
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Arformoterol 50 microg QD
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Salmeterol 42 microg BID
Number of subjects: 717

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 717
Study: 14643168

Group type: EXPERIMENTAL
Intervention: Ambroxol (75 mg twice daily)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Ambroxol (75 mg twice daily) in patients with more severe symptoms
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo in patients with more severe symptoms
Number of subjects: 242
Study: 11739832

Group type: EXPERIMENTAL
Intervention: 50 U botulinum toxin type A
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100 U botulinum toxin type A
Number of subjects: 24
Study: 9003220

Group type: EXPERIMENTAL
Intervention: Bovine casein
Number of subjects: 0

Group type: COMPARATOR
Intervention: House dust mite antigens
Number of subjects: 0
Study: 8492965

Group type: EXPERIMENTAL
Intervention: High dose methotrexate (7500 mg/m2)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low dose methotrexate (750 mg/m2)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 23
Study: 3498356

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 31368893

Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Proximal-segment DCB
Number of subjects: 442

Group type: COMPARATOR
Intervention: PTA
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Overall ITT DCB
Number of subjects: 442

Group type: COMPARATOR
Intervention: Overall ITT PTA
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: DCB
Number of subjects: 442
Study: 28931055

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia for 72 hours
Number of subjects: 75

Group type: COMPARATOR
Intervention: Normothermic treatment
Number of subjects: 75
Study: 25908089

Group type: EXPERIMENTAL
Intervention: Stenting plus best medical treatment
Number of subjects: 115

Group type: COMPARATOR
Intervention: Medical treatment alone
Number of subjects: 115
Study: 23427864

Group type: EXPERIMENTAL
Intervention: sitagliptin
Number of subjects: 453

Group type: COMPARATOR
Intervention: glibenclamide
Number of subjects: 453

Group type: COMPARATOR
Intervention: metformin monotherapy
Number of subjects: 453

Group type: COMPARATOR
Intervention: metformin+pioglitazone combination
Number of subjects: 453
Study: 21295767

Group type: EXPERIMENTAL
Intervention: DBT‐based skills training (n=26)
Number of subjects: 51
Study: 19368145

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus Aloe arborescens (10 ml thrice daily)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus Aloe arborescens
Number of subjects: 240
Study: 16442593

Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2 every 3-week cycle) and carboplatin (area under the curve of 5 every 3-week cycle)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mitoxantrone (12 mg/m2 every 3-week cycle)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mitoxantrone
Number of subjects: 40
Study: 14755192

Group type: EXPERIMENTAL
Intervention: Halothane-Propofol
Number of subjects: 46

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 46
Study: 11424018

Group type: EXPERIMENTAL
Intervention: Topical resiquimod gel 0.01% (twice or thrice weekly) or 0.05% (once or twice weekly)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Resiquimod-treated patients
Number of subjects: 52

Group type: COMPARATOR
Intervention: Vehicle-treated patients
Number of subjects: 52
Study: 8618466

Group type: EXPERIMENTAL
Intervention: Induction therapy of varying intensities (specific details not provided)
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Induction treatment (specific details not provided)
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Prognostic index based on age, LDH, M3 morphology, and karyotype
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Age over 60
Number of subjects: 1034
Study: 1533542

Group type: EXPERIMENTAL
Intervention: 6 mg kg‐1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 12 mg kg‐1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6 and 12 mg kg‐1
Number of subjects: 10
Study: 10268818

Group type: EXPERIMENTAL
Intervention: Experimental nursing intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pretest characteristics
Number of subjects: 0
Study: 31418422

Group type: EXPERIMENTAL
Intervention: PiP program (tailored web-based parenting intervention)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Educational factsheets (active control)
Number of subjects: 359
Study: 29077637

Group type: EXPERIMENTAL
Intervention: 60 maximal knee flexor eccentric contractions (60MaxEC)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 60MaxEC at 1 day later
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 60MaxEC at 7 days later
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 60MaxEC at 28 days later
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group performing 60MaxEC separated by 14 d
Number of subjects: 39
Study: 26921083

Group type: EXPERIMENTAL
Intervention: Xanthan gum OVB slurry
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Honey OVB slurry
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sucralose OVB slurry
Number of subjects: 24
Study: 25156968

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (40 mg/d)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Flaxseed oil supplementation (2 g/d)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Change in serum glucose concentrations
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Change in HOMA-IR
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 48
Study: 22192409

Group type: EXPERIMENTAL
Intervention: Cognitive distraction tasks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Conditioned pain modulation (CPM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of CPM and distraction
Number of subjects: 30

Group type: COMPARATOR
Intervention: CPM
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cognitive distraction
Number of subjects: 30
Study: 20338728

Group type: EXPERIMENTAL
Intervention: Ketoprofen administered 60 min preoperatively
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ketoprofen administered 60 min postoperatively
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (no ketoprofen)
Number of subjects: 96
Study: 18843872

Group type: EXPERIMENTAL
Intervention: Oral pilocarpine (5 mg) 1-tablet three times daily for three months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo 1-tablet three times daily for the first month
Number of subjects: 33
Study: 16028634

Group type: EXPERIMENTAL
Intervention: Single high vitamin A intake with a liver meal (up to 120,000 IU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooling results with literature data
Number of subjects: 0
Study: 11842071

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise training (40% VO(2 max))
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (70% VO(2 max))
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 24
Study: 10365036

Group type: EXPERIMENTAL
Intervention: Topcon ImageNet (TI) system
Number of subjects: 28

Group type: COMPARATOR
Intervention: Heidelberg retina tomograph (HRT)
Number of subjects: 28
Study: 8749165

Group type: EXPERIMENTAL
Intervention: Linear acceleration in a space‐fixed imaginary gaze condition (LSEM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acoustic pursuit of a moving sound source (SSPEM)
Number of subjects: 0
Study: 1525750

Group type: EXPERIMENTAL
Intervention: Peer Assisted Learning (PAL) prevention program
Number of subjects: 0
Study: 3894551

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine medication (one active medication patch)
Number of subjects: 30
Study: 31009327

Group type: EXPERIMENTAL
Intervention: Triclosan-coated PDS
Number of subjects: 890

Group type: COMPARATOR
Intervention: Standard PDS
Number of subjects: 890
Study: 30360970

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg orally once daily for 12 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo orally once daily for 12 weeks
Number of subjects: 116
Study: 26861663

Group type: EXPERIMENTAL
Intervention: NewBrace (brace designed using CAD/CAM and FEM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CtrlBrace (brace designed using conventional CAD/CAM)
Number of subjects: 40
Study: 23360100

Group type: EXPERIMENTAL
Intervention: 20 IU AVP (administered nasally)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (administered nasally)
Number of subjects: 36
Study: 20874726

Group type: EXPERIMENTAL
Intervention: Zaditen (Ketotifen)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 103
Study: 19153534

Group type: EXPERIMENTAL
Intervention: Leukotriene modifier (LM)
Number of subjects: 18
Study: 17125829

Group type: EXPERIMENTAL
Intervention: Two-step self-etching primers (Clearfil SE Bond, Clearfil Protect Bond)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Two-step etch-and-rinse adhesives (Single Bond, Prime&Bond NT)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: One-step self-etching adhesive (One-up Bond F)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: All groups after storage in oil
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Two-step self-etching primers (especially Clearfil Protect Bond)
Number of subjects: 5
Study: 15305186

Group type: EXPERIMENTAL
Intervention: Capecitabine at 2000 mg m(‐2) day(‐1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Capecitabine at 1800 mg m(‐2) day(‐1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Capecitabine (various dose levels)
Number of subjects: 28
Study: 11284824

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway
Number of subjects: 75

Group type: COMPARATOR
Intervention: Laryngeal mask airway
Number of subjects: 75
Study: 9082037

Group type: EXPERIMENTAL
Intervention: Palm oil (PA) diet
Number of subjects: 151

Group type: COMPARATOR
Intervention: Lard (LA) diet
Number of subjects: 151

Group type: COMPARATOR
Intervention: Peanut oil (PE) diet
Number of subjects: 151
Study: 8400675

Group type: EXPERIMENTAL
Intervention: Indomethacin (IDM) 50 mg every 8 hours for 4 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no IDM or other non-steroidal anti-inflammatory drug)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indomethacin (IDM)
Number of subjects: 20
Study: 2870233

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 1
Study: 29703528

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplements (fish oil and flaxseed oil)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study: 26321018

Group type: EXPERIMENTAL
Intervention: Intranasal administration of arginine vasopressin 1A and 1B receptor agonist
Number of subjects: 109

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 109

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 109

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 109
Study: 23972565

Group type: EXPERIMENTAL
Intervention: Minimally invasive (MIS) total knee arthroplasty
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard medial parapatellar approach (control)
Number of subjects: 86
Study: 23033299

Group type: EXPERIMENTAL
Intervention: Foam dressings with silver (Group A)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Foam dressings without silver (Group B)
Number of subjects: 26
Study: 20237499

Group type: EXPERIMENTAL
Intervention: ARCSolver method (oscillometric method)
Number of subjects: 302

Group type: COMPARATOR
Intervention: SphygmoCor method (tonometric system)
Number of subjects: 302
Study: 18341378

Group type: EXPERIMENTAL
Intervention: Amifostine (300 mg/m2 intravenously before 131I administration)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nontreated group (Control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dose of 131I
Number of subjects: 80
Study: 15724236

Group type: EXPERIMENTAL
Intervention: nateglinide
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 12213943

Group type: EXPERIMENTAL
Intervention: Reviparin (1750 anti-Xa units given once daily)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study: 10605275

Group type: EXPERIMENTAL
Intervention: Modified Balters appliance (USA UNC, Chapel Hill)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: U‐bow activator Type I (Germany WWU Münster)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (untreated malocclusions, USA UNC, Chapel Hill)
Number of subjects: 3
Study: 7485128

Group type: EXPERIMENTAL
Intervention: L-carnitine (1 g intravenously after every dialysis session for 6 months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 24
Study: 2025806

Group type: EXPERIMENTAL
Intervention: Custom-made braces (Generation II Polyaxial Knee Cage and Lenox Hill Derotation Brace)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Off-the-shelf braces
Number of subjects: 10
Study: 6988106

Group type: EXPERIMENTAL
Intervention: Flunisolide (200 micrograms total: 25 micrograms/actuation, 2 actuations into each nostril twice a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (400 micrograms total: 50 micrograms/actuation, 1 actuation in each nostril four times a day)
Number of subjects: 60
Study: 31461146

Group type: EXPERIMENTAL
Intervention: Free self-tests
Number of subjects: 3996

Group type: EXPERIMENTAL
Intervention: Self-tests for US $0.50
Number of subjects: 3996

Group type: EXPERIMENTAL
Intervention: Self-tests for $1, $2, and $3
Number of subjects: 3996

Group type: EXPERIMENTAL
Intervention: Pharmacy-based distribution
Number of subjects: 3996

Group type: EXPERIMENTAL
Intervention: Promotional messages
Number of subjects: 3996
Study: 28336454

Group type: EXPERIMENTAL
Intervention: Cryoneurolysis targeting the infrapatellar branch of the saphenous nerve (IPBSN)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 180
Study: 25880498

Group type: EXPERIMENTAL
Intervention: Educational group program of eight sessions every 3 months led by trained nurses with tailored semi-automated SMS support.
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: Short educational program for primary care professionals including a decision support tool and monthly feedback report.
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: Combination of educational interventions for patients and professionals.
Number of subjects: 2300

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: All groups (1, 2, and 3) will also be assessed for secondary endpoints: cardiovascular risk factors, macrovascular and microvascular diabetes complications, quality of life, psychological outcomes, diabetes knowledge, and healthcare utilization.
Number of subjects: 2300
Study: 23414626

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 39
Study: 21325473

Group type: EXPERIMENTAL
Intervention: High-soy diet (2 servings/day: 177 mL soy milk, 126 g tofu, or 23 g soy nuts) for 6 months
Number of subjects: 96

Group type: COMPARATOR
Intervention: Low-soy diet (<3 servings/week) for 6 months
Number of subjects: 96
Study: 19919978

Group type: EXPERIMENTAL
Intervention: Corin I555(P568) allele
Number of subjects: 354

Group type: COMPARATOR
Intervention: Fixed-dose combination isosorbide-dinitrate/hydralazine
Number of subjects: 354
Study: 17578938

Group type: EXPERIMENTAL
Intervention: Motor-level 2-Hz TENS
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sensory-level 80-Hz TENS
Number of subjects: 33

Group type: COMPARATOR
Intervention: Subliminal 80-Hz TENS
Number of subjects: 33
Study: 15090059

Group type: EXPERIMENTAL
Intervention: Tones delivered at the ipsilateral ear (right) at increasing intensities (60, 70, 80 dBA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Concurrent tone of constant intensity delivered dichotically at the contralateral ear (left)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Contralateral tone fundamental frequency similar to ipsilateral tone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dichotic listening conditions
Number of subjects: 10
Study: 11179529

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 214
Study: 9752815

Group type: EXPERIMENTAL
Intervention: Prolonged polychemotherapy
Number of subjects: 18000

Group type: COMPARATOR
Intervention: Anthracycline-containing regimens
Number of subjects: 18000
Study: 8017815

Group type: EXPERIMENTAL
Intervention: Suprapubic Ingram Trocar
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Add‐a‐Cath
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard Foley catheter
Number of subjects: 70
Study: 2807359

Group type: EXPERIMENTAL
Intervention: Low dose Metoprolol (0.36 to 0.65 mg/kg/day)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Low dose Metoprolol (0.66 to 0.99 mg/kg/day)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Low dose Metoprolol (1 to 1.81 mg/kg/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Comparison with Goteberg Metoprolol trial and MIAMI trials (200 mg/day)
Number of subjects: 37
Study: 1103934

Group type: EXPERIMENTAL
Intervention: 2% miconazole in cream and powder base
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 45
Study: 31926893

Group type: EXPERIMENTAL
Intervention: Erbium glass, 1540 nm laser treatment 24 hours before surgery
Number of subjects: 11

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 11
Study: 31147247

Group type: EXPERIMENTAL
Intervention: Conversion THA
Number of subjects: 389
Study: 28608804

Group type: EXPERIMENTAL
Intervention: ω3-milk
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PhyS-milk
Number of subjects: 32
Study: 25882987

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 647

Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 647
Study: 24384588

Group type: EXPERIMENTAL
Intervention: Atazanavir-ritonavir (ATV/r)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Abacavir-lamivudine (ABC/3TC)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Tenofovir DF-emtricitabine (TDF/FTC)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Increased lean body mass (LBM)
Number of subjects: 269
Study: 21387016

Group type: EXPERIMENTAL
Intervention: Participants susceptible to auditory illusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants not prone to illusory discontinuity
Number of subjects: 0
Study: 19016092

Group type: EXPERIMENTAL
Intervention: Group psychosocial intervention
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waitlist-control
Number of subjects: 44
Study: 16542606

Group type: EXPERIMENTAL
Intervention: PANSS positive symptoms
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PANSS negative symptoms
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aggression risk profile scores
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Composite scores
Number of subjects: 100
Study: 12855928

Group type: EXPERIMENTAL
Intervention: High intensity stationary cycling (EXER)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 100 mg/d spironolactone (DIUR)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Exercise and diuretic (EXDI)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 21
Study: 11239617

Group type: EXPERIMENTAL
Intervention: 200 mg oral mifepristone followed by 800 microg vaginal misoprostol at 24, 48, or 72 h
Number of subjects: 2302
Study: 8703859

Group type: EXPERIMENTAL
Intervention: Isoproterenol (0.1 microgram/min)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Phenylephrine (peripheral vasoconstrictor)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sodium nitroprusside (non-specific vasodilator)
Number of subjects: 19